Healthcare worker-based opportunistic screening for familial hypercholesterolemia in a low-resource setting.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
07
2021
accepted:
24
05
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
Heterozygous familial hypercholesterolemia (FHeH) is important risk factor for premature coronary artery disease (CAD). Strategies for its diagnosis and prevalence have not been well studied in India. We performed healthcare worker-based opportunistic screening to assess feasibility for determining its prevalence. A healthcare worker was trained in use of Dutch Lipid Clinic Network (DLCN) criteria for diagnosis of FHeH. Successive eligible individuals (n = 3000 of 3450 screened) presenting to biochemistry laboratories of two hospitals for blood lipid measurements were evaluated for FHeH. Cascade screening or genetic studies were not performed. Descriptive statistics are reported. We included 2549 participants (men 1870, women 679) not on statin therapy. Health worker screened 25-30 individuals/day in 6-10 minutes each. The mean age was 46.2±11y. Variables of DLCN criteria were more in women vs men: family history 51.1 vs 35.6%, past CAD 48.2 vs 20.1%, arcus cornealis 1.1 vs 0.3%, tendon xanthoma 0.3 vs 0.1%, and LDL cholesterol 190-249 mg/dl in 8.5 vs 2.4%, 250-329 mg/dl in 0.7 vs 0% and ≥330 mg/dl in 0.3 vs 0% (p<0.01). Definite FHeH (DLCN score >8) was in 15 (0.59%, frequency 1:170) and probable FHeH (score 6-8) in 87 (3.4%, frequency 1:29). The prevalence was significantly greater in women, age <50y and in those with hypertension, diabetes and known CAD. Healthcare worker-led opportunistic screening for diagnosis of FHeH using DLCN criteria is feasible in low-resource settings. The results show significant prevalence of clinically detected definite and probable FHeH in the population studied.
Sections du résumé
BACKGROUND & OBJECTIVE
Heterozygous familial hypercholesterolemia (FHeH) is important risk factor for premature coronary artery disease (CAD). Strategies for its diagnosis and prevalence have not been well studied in India. We performed healthcare worker-based opportunistic screening to assess feasibility for determining its prevalence.
METHODS
A healthcare worker was trained in use of Dutch Lipid Clinic Network (DLCN) criteria for diagnosis of FHeH. Successive eligible individuals (n = 3000 of 3450 screened) presenting to biochemistry laboratories of two hospitals for blood lipid measurements were evaluated for FHeH. Cascade screening or genetic studies were not performed. Descriptive statistics are reported.
RESULTS
We included 2549 participants (men 1870, women 679) not on statin therapy. Health worker screened 25-30 individuals/day in 6-10 minutes each. The mean age was 46.2±11y. Variables of DLCN criteria were more in women vs men: family history 51.1 vs 35.6%, past CAD 48.2 vs 20.1%, arcus cornealis 1.1 vs 0.3%, tendon xanthoma 0.3 vs 0.1%, and LDL cholesterol 190-249 mg/dl in 8.5 vs 2.4%, 250-329 mg/dl in 0.7 vs 0% and ≥330 mg/dl in 0.3 vs 0% (p<0.01). Definite FHeH (DLCN score >8) was in 15 (0.59%, frequency 1:170) and probable FHeH (score 6-8) in 87 (3.4%, frequency 1:29). The prevalence was significantly greater in women, age <50y and in those with hypertension, diabetes and known CAD.
CONCLUSIONS
Healthcare worker-led opportunistic screening for diagnosis of FHeH using DLCN criteria is feasible in low-resource settings. The results show significant prevalence of clinically detected definite and probable FHeH in the population studied.
Identifiants
pubmed: 35679249
doi: 10.1371/journal.pone.0269605
pii: PONE-D-21-22681
pmc: PMC9182245
doi:
Substances chimiques
Cholesterol, LDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269605Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
BMC Public Health. 2019 Jun 27;19(1):837
pubmed: 31248412
Indian J Pediatr. 2018 May;85(5):339-343
pubmed: 29450819
Lancet Diabetes Endocrinol. 2016 Oct;4(10):850-61
pubmed: 27246162
J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64
pubmed: 22893714
Nature. 2020 Jun;582(7810):73-77
pubmed: 32494083
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566
pubmed: 32439005
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004015
pubmed: 15674924
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Indian Heart J. 2014 May-Jun;66(3):280-8
pubmed: 24973832
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Eur Heart J. 2020 Jun 21;41(24):2313-2330
pubmed: 32052833
Indian Heart J. 2017 May - Jun;69(3):382-392
pubmed: 28648438
Hum Resour Health. 2017 Apr 13;15(1):29
pubmed: 28407810
Heart. 2021 May 20;:
pubmed: 34016696
Circ Genom Precis Med. 2021 Feb;14(1):e003120
pubmed: 33480803
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
Lancet. 2019 Aug 24;394(10199):685-696
pubmed: 31448740
J Clin Lipidol. 2017 Jul - Aug;11(4):1013-1022
pubmed: 28826564
Am Heart J. 2014 Nov;168(5):690-7
pubmed: 25440797
J Am Heart Assoc. 2019 Dec 17;8(24):e013225
pubmed: 31838973
J Clin Lipidol. 2020 Jan - Feb;14(1):35-45
pubmed: 32044282
BMJ Open. 2017 Sep 01;7(9):e016461
pubmed: 28864697
J Endocr Soc. 2020 Aug 21;5(1):bvaa122
pubmed: 33928199
N Engl J Med. 2019 Oct 17;381(16):1557-1567
pubmed: 31618541
Indian Heart J. 2019 Mar - Apr;71(2):118-122
pubmed: 31280822
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Heart. 2021 May 20;:
pubmed: 34016698
J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89
pubmed: 27050191
Cardiovasc Ther. 2020 Jun 11;2020:5936748
pubmed: 32636924